| Literature DB >> 26381645 |
Miao Yu1, XiaoWei Tang2, Xiang Wang3, XiangRong Zhang4, XiaoBin Zhang2, WeiWei Sha2, ShuQiao Yao3, Ni Shu5, XiangYang Zhang6, ZhiJun Zhang1.
Abstract
BACKGROUND: Deficit schizophrenia (DS) has been proposed as a pathophysiologically distinct subgroup within schizophrenia. Earlier studies focusing on neurocognitive function of DS patients have yielded inconsistent findings ranging from substantial deficits to no significant difference relative to non-deficit schizophrenia patients (NDS). The present study investigated the severity and characteristic patterns of neurocognitive impairments in DS and NDS patients and their relationships with clinical variables.Entities:
Mesh:
Year: 2015 PMID: 26381645 PMCID: PMC4575183 DOI: 10.1371/journal.pone.0138357
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographics and clinical characteristics for DS, NDS and HC groups.
| DS (n = 40) | NDS (n = 57) | HC (n = 52) |
|
| |
|---|---|---|---|---|---|
| Age (years) | 49.38±7.29 | 46.14±7.18 | 45.81±8.77 | 2.795 | 0.064 |
| Education (years) | 8.98±1.97 | 8.91±1.85 | 10.42±2.75 | 7.513 | 0.001 |
| Age at Onset (years) | 21.80±2.92 | 22.35±2.49 | -0.999 | 0.320 | |
| Duration of illness (years) | 27.58±6.89 | 23.79±7.19 | 2.596 | 0.011 | |
| BPRS total score | 31.88±2.86 | 27.49±2.76 | 7.591 | <0.001 | |
| Positive syndrome | 6.23±1.19 | 6.40±1.16 | -0.738 | 0.462 | |
| Negative syndrome | 12.30±1.62 | 7.49±1.00 | 16.665 | <0.001 | |
| Disorganized syndrome | 6.48±1.01 | 6.54±0.97 | -0.339 | 0.735 | |
| Affect | 6.88±1.11 | 7.05±1.27 | -0.711 | 0.479 | |
| SANS total score | 56.35±8.35 | 32.30±6.57 | 15.861 | <0.001 | |
| SAPS total score | 9.20±3.92 | 10.19±5.06 | -1.042 | 0.300 | |
| SDS total score | 10.95±2.42 | 4.16±2.35 | 13.844 | <0.001 | |
| avolition | 5.88±1.62 | 2.47±1.42 | 10.972 | <0.001 | |
| poor emotional expression | 5.08±1.10 | 1.68±1.17 | 14.442 | <0.001 | |
| Smoking ratio (%) | 65.00 | 70.20 | 0.290 | 0.591 | |
| Antiparkinson agent ratio (%) | 42.5 | 35.1 | 0.547 | 0.459 | |
| Benzodiazepine agent ration (%) | 20.0 | 15.8 | 0.288 | 0.591 | |
| CPZ-equivalent daily dose (mg/day) | 496.88±217.54 | 506.84±211.08 | -0.226 | 0.822 |
Note: DS: deficit schizophrenia; NDS: non-deficit schizophrenia; HC: healthy controls; BPRS: Brief Psychiatric Rating Scale; SANS: the Scale for the Assessment of Negative Symptoms; SAPS: the Scale for the Assessment of Positive Symptoms; SDS: schedule for the deficit syndrome; CPZ: chlorpromazine;
** p <0.001 DS vs. NDS;
* p <0.05 DS vs. NDS;
△ p <0.05 DS vs. HC;
# p <0.05 NDS vs. HC.
Comparisons of raw neuropsychological performance among DS, NDS and HC groups.
| DS (n = 40) | NDS (n = 57) | HC (n = 52) |
|
| |
|---|---|---|---|---|---|
| Animal Naming test | 9.57±3.13 | 12.33±4.38 | 17.62±4.59 | 37.486 | <0.001 |
| COWAT | 4.95±3.05 | 6.95±3.67 | 8.94±2.29 | 15.117 | <0.001 |
| Digit vigilance test (seconds) | 285.77±121.60 | 187.58±94.14 | 135.49±39.74 | 25.490 | <0.001 |
| TMT-A (seconds) | 131.28±69.45 | 77.04 ±32.86 | 48.77±21.19 | 34.665 | <0.001 |
| TMT-B (seconds) | 283.76±145.70 | 196.99±55.11 | 119.11±60.25 | 29.309 | <0.001 |
| Stroop words only | 45.28±20.00 | 59.28±17.62 | 78.92±16.10 | 33.364 | <0.001 |
| Stroop colors only | 27.40±12.81 | 36.56±11.29 | 50.63±13.89 | 30.984 | <0.001 |
| Stroop interference | 17.78±10.22 | 21.82±8.62 | 32.06±10.17 | 21.383 | <0.001 |
| Spatial processing (Block design) | 11.58±4.54 | 13.79 ±3.48 | 17.63±3.36 | 23.293 | <0.001 |
| WAIS-RC (Block Design) | 12.88±8.93 | 21.91±7.02 | 28.52±8.22 | 35.423 | <0.001 |
Note: COWAT: Controlled Oral Word Association test; TMTA&B: Trail Making Tests A&B; WAIS-RC: Wechsler adult intelligence scale (Chinese version); DS: deficit schizophrenia; NDS: non-deficit schizophrenia; HC: healthy controls;
** p <0.001 DS vs. NDS;
* p <0.05 DS vs. NDS;
△△ p <0.001 DS vs. HC;
## p <0.001 NDS vs. HC;
# p <0.05 NDS vs. HC.
Descriptive statistics of domain-specific composite scores, effect sizes and Cronbach’s alpha for each cognitive domain.
| Cognitive domain | DS (n = 40) | NDS (n = 57) | Effect size (Cohen’s | Cronbach's Alpha |
|---|---|---|---|---|
| Sustained vigilance/Attention | -11.44±6.65 | -4.88±4.25 | 1.176 | 0.803 |
| Ideation fluency | -3.50±1.74 | -2.02±2.22 | 0.742 | 0.673 |
| Cognitive flexibility | -4.14 ±2.97 | -2.30±1.45 | 0.787 | 0.661 |
| Visuospatial memory | -3.71±1.92 | -1.95±1.53 | 1.014 | 0.648 |
Note: Patients’ neuropsychological test scores were standardized using the healthy control group data. Sustained vigilance/attention domain includes Stroop words only and colors only, Trail making test part A and Digit vigilance test. Ideation fluency domain includes Controlled Oral Word Association test and Animal Naming Test. Cognitive flexibility includes Stroop color/word interference test and Trail making test part B. Visuospatial memory domain includes Spatial processing test and Wechsler adult intelligence scale (Block Design, Chinese version). DS: deficit schizophrenia; NDS: non-deficit schizophrenia.
Fig 1Profile analysis for neuropsychological tests and cognitive domains of DS and NDS groups.
Note: Profile analysis for (a) neuropsychological tests and (b) cognitive domains of DS and NDS groups. ST word: Stroop word only; ST col: Stroop color only; TMTA&B: Trail Making Tests A&B; DVT: Digit vigilance test; ANT: Animal Naming test; COWAT: Controlled Oral Word Association test; ST int: Stroop interference test; SP: Spatial processing (Block Design); WAIS-RC: Wechsler adult intelligence scale (Block Design, Chinese version); SV: Sustained vigilance/attention; IF: Ideation fluency; CF: Cognitive flexibility; VM: Visuospatial memory. The error bars on Fig 1 was standard errors.
Fig 2The multiple regression analyses for relationships between clinical features and cognitive domains in DS and NDS group, respectively.
Note: The relationships between clinical variables and cognitive domains impairments in (a) DS group and (b) NDS group were carried out with the hierarchical regression analyses. The numerical values represent standardized beta weights.